Ogura, K., Goto, T., Imanishi, J., Shinoda, Y., Okuma, T., Tsuda, Y., Kobayashi, H., Akiyama, T., Hirata, M., Yamamoto, A. and Kawano, H. (2013) Neoadjuvant and Adjuvant Chemotherapy with Modified Mesna, Adriamycin, Ifosfamide, and Dacarbazine (MAID) Regimen for Adult High-Grade Non-Small Round Cell Soft Tissue Sarcomas. International Journal of Clinical Oncology, 18, 170-176.
http://dx.doi.org/10.1007/s10147-011-0360-x

has been cited by the following article:

• TITLE: Risk Factors Associated with In-Hospital Post-Chemotherapy Mortality in Patients with Malignant Musculoskeletal Tumors

  AUTHORS: Toru Akiyama, Kazuo Saita, Hirotaka Chikuda, Hiromasa Horiguchi, Kiyohide Fushimi, Hideo Yasunaga

  KEYWORDS: Chemotherapy, Sarcoma, In-Hospital Mortality, Chemotherapy-Related Death, Japanese Diagnosis Procedure Combination Database

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.6, June 1, 2016

  ABSTRACT: Introduction: Reducing the in-hospital post-chemotherapy mortality rate in patients with malignant musculoskeletal tumors is important for improving treatment outcome. This study aimed to investigate the risk factors associated with in-hospital post-chemotherapy mortality in patients with primary malignant musculoskeletal tumors. Methods: Using a Japanese national inpatient database, we retrospectively identified 5039 patients (2920 men and 2131 women; mean age, 39 years) who underwent curative chemotherapy for malignant musculoskeletal tumors between 2007 and 2010. We extracted data on the patients’ characteristics, complications, chemotherapeutic agent use, comorbidities, and in-hospital death. Logistic regression analyses were performed to analyze factors affecting in-hospital post-chemotherapy death in these patients. Results: The overall in-hospital mortality rate was 1.1%. Higher in-hospital mortality rates were significantly associated with a greater volume of blood transfusion (>2500 mL) (odds ratio [OR], 49.71; 95% confidence interval [CI], 22.24 - 111.12; p